Thomas P. Steindler, head of the Intellectual Property Litigation Practice Group in Washington, DC, focuses his practice on intellectual property litigation along with complex commercial and administrative litigation. He has appeared in state and federal courts at all levels and has argued before the US Supreme Court. He is consistently recognized by Washington Super Lawyers as one of the leading intellectual property litigators in Washington, DC.
In the intellectual property arena, Thomas has acted as lead counsel in patent litigation across the country in a wide variety of industries, including pharmaceuticals, vaccines, diagnostics, medical devices and other industries, at the district court level and in the Federal Circuit. In addition, he has handled licensing and collaboration disputes, false advertising and false patent marking cases, as well as trade secret/non-compete cases.
In the commercial and administrative arena, Thomas has handled a wide range of matters extending from savings and loan goodwill cases to appeals of telecommunications regulations.
Acted as lead counsel for Sandoz, Inc., in Hatch-Waxman litigation against Janssen Pharmaceuticals, Inc., and Shionogi & Co., Ltd., related to an antibiotic medication
Acted as lead counsel for Sandoz, Inc., in patent litigation against Amphastar Pharmaceuticals, Inc., Actavis, Inc., and Teva Pharmaceuticals USA, Inc., related to an anticoagulant medication
Acted as lead counsel for Novartis Pharma AG in patent litigation against Biogen Idec, Inc., Medimmune, LLC, and Alexion Pharmaceuticals, Inc., related to improved expression systems for recombinant proteins using CMV Promoter technology
Acted as lead counsel for Novartis Vaccines and Diagnostics, Inc., in patent litigation against Microbix, Inc., related to an egg-based process for manufacturing flu vaccines, including acting as global coordinator of companion patent litigation in Germany and Italy
Acted as lead counsel for Novartis Vaccines and Diagnostics, Inc., in arbitration proceedings against Ortho Clinical Diagnostics, Inc., for disputes arising out of a joint business agreement for the development and sale of diagnostic products to detect hepatitis viruses and human immunodeficiency viruses using recombinant DNA and antibody technologies
Acted as lead counsel for Novartis Vaccines and Diagnostics, Inc., in a judicial appeal by Alphavax, Inc., of an adverse decision by the Board of Patent Appeals and Interferences in an interference proceeding relating to vaccination methods using alphaviruses
Represented Novartis Vaccines and Diagnostics, Inc., in interference proceeding at the US Patent and Trademark Office against Sanofi on counts related to conjugate vaccines to prevent meningitis
Acted as lead counsel for Alcon Laboratories, Inc., in a series of disputes with collaboration partners related to contact lenses and intraocular lenses designs
Represented CIBA Vision and Alcon Laboratories, Inc., in a series of Lanham Act/false advertising disputes related to contact lenses and intraocular lenses
Acted as lead counsel for CIBA Vision Corporation in patent litigation against Johnson & Johnson Vision Care, Inc., related to silicone hydrogel contact lens technology, including acting as global coordinator of companion pan-European patent litigation
Represented Wesley Jessen Corp. in patent litigation against Bausch & Lomb related to silicone hydrogel contact lens technology
US Court of Appeals for the District of Columbia Circuit
US Court of Appeals for the Fourth Circuit
US Court of Appeals for the Seventh Circuit
US Court of Appeals for the Eighth Circuit
US Court of Appeals for the Ninth Circuit
US Court of Appeals for the Eleventh Circuit
US District Court for the District of Columbia
US Court of Federal Claims
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.